← 홈

프로그램 비교

검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-14 · 마지막 7월 13일

현재 선택: 2

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

API CSV24행 · 2개 프로그램

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
ADCPhase 3
sacituzumab govitecan (Trodelvy)
Gilead / Immunomedics·Locally Advanced or Metastatic Uro…
ORR 44%·t½ 24 h
ADCFDAApproved
enfortumab vedotin (Padcev)
Astellas / Seagen·Renal Pelvis and Ureter Urothelial…
ORR 44%·t½ 3.6 h
Overview
Program
Sacituzumab GovitecanEnfortumab Vedotin
Overview
Company
Gilead / ImmunomedicsAstellas / Seagen
Overview
Modality
ADCADC
Overview
Target
Locally Advanced or Metastatic UrotheliaRenal Pelvis and Ureter Urothelial Carci
Overview
Indication
Breast Cancer; Metastatic Breast CancerMetastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Overview
Phase
PHASE_3APPROVED
Overview
Status
RECRUITINGRECRUITING
MoA
Mechanism
and current clinical applications, discussing its therapeutic potential in the context of CRCADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation
MoA
Biomarker
TROP2 glycoprotein, which is highbiomarkers are limited
PK/PD
Half-life
24 h3.6 h
PK/PD
Species
Minipig, PigMouse, Human
PK/PD
Animal (cat.)
UnknownHuman, Mouse, In vitro
PK/PD
Experiment
pharmacokineticPharmacokinetic
Toxicology
Species
Cynomolgus monkey, Minipig, Pig, HamsterCynomolgus monkey, Mouse, Rat, Human
Toxicology
Animal (cat.)
NHPMouse, Rat, NHP
Toxicology
Major finding
interstitial lung disease accounted for 1Interstitial Lung Disease (ILD): Severe, life-threatening or fatal pneumonitis/ILD may occur
Clinical
Primary efficacy
ORR 44%ORR 44%
Clinical
ORR
44.0%39%
Clinical
PFS
5.8
Clinical
OS
12.4
Clinical
Result source
ClinicalTrials.gov NCT04916002ClinicalTrials.gov NCT03219333
Clinical
Data Tier / Score
C · 56S · 88
Clinical
Program phase
PHASE_3APPROVED
Clinical
Clinical sync
2026년 7월 6일 (8일 전)2026년 7월 4일 (9일 전)